Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.44 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19181066 | 1.00 | MMP9 (0.47) | MMP9CYP19A1AGTR2FKBP1ABACE1 | |
| SCHEMBL24938940 | 0.90 | FKBP1A (0.43) | CYP19A1FKBP1ATRPM8 | |
| SCHEMBL24251891 | 0.86 | MMP9 (0.45) | MMP9AGTR2BACE1CYP2C19 | |
| SCHEMBL29385791 | 0.85 | AGTR2 (0.46) | MMP9AGTR2FKBP1ABACE1CYP2C19 | |
| SCHEMBL13729227 | 0.85 | AGTR2 (0.46) | MMP9AGTR2FKBP1ABACE1CYP2C19 | |
| SCHEMBL31127193 | 0.82 | MMP2 (0.46) | CYP19A1FKBP1ATRPM8 | |
| SCHEMBL2276952 | 0.82 | FKBP1A (0.54) | CYP19A1FKBP1ATRPM8 | |
| SCHEMBL13613076 | 0.81 | POLB (0.48) | AGTR2FKBP1A | |
| SCHEMBL5368566 | 0.81 | CYP3A4 (0.50) | FKBP1A | |
| SCHEMBL24938939 | 0.81 | CYP3A4 (0.50) | FKBP1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11696917-B2 | Agent enhancing antitumor effect using pyrazolo[3,4-d]pyrimidine compound | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2023-07-11 | — | — | US | disclosed |
| US-20200061067-A1 | AGENT ENHANCING ANTITUMOR EFFECT USING PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11696917-B2 | Agent enhancing antitumor effect using pyrazolo[3,4-d]pyrimidine compound | ZYX, DPYD, ZFX | MMP9 3034/4885CYP19A1 4410/4885AGTR2 2402/4885 |
| US-20200061067-A1 | AGENT ENHANCING ANTITUMOR EFFECT USING PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND | ZYX, DPYD, ZFX | MMP9 3034/4885CYP19A1 4410/4885AGTR2 2402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.